RU95107090A - Immunoprobiotic preparation - Google Patents
Immunoprobiotic preparationInfo
- Publication number
- RU95107090A RU95107090A RU95107090/13A RU95107090A RU95107090A RU 95107090 A RU95107090 A RU 95107090A RU 95107090/13 A RU95107090/13 A RU 95107090/13A RU 95107090 A RU95107090 A RU 95107090A RU 95107090 A RU95107090 A RU 95107090A
- Authority
- RU
- Russia
- Prior art keywords
- dry
- following ratio
- components
- stabilizing
- buffer system
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract 5
- 230000000087 stabilizing effect Effects 0.000 claims abstract 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract 6
- 230000001580 bacterial effect Effects 0.000 claims abstract 5
- 239000007853 buffer solution Substances 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 239000002028 Biomass Substances 0.000 claims abstract 4
- 239000002955 immunomodulating agent Substances 0.000 claims abstract 4
- 230000000529 probiotic effect Effects 0.000 claims abstract 3
- 239000011780 sodium chloride Substances 0.000 claims abstract 3
- 241000894006 Bacteria Species 0.000 claims abstract 2
- 241000186160 Bifidobacterium pseudolongum subsp. globosum Species 0.000 claims abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract 2
- 241001465754 Metazoa Species 0.000 claims abstract 2
- 229920002472 Starch Polymers 0.000 claims abstract 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract 2
- 230000000403 immunocorrecting effect Effects 0.000 claims abstract 2
- 210000000936 intestine Anatomy 0.000 claims abstract 2
- 239000008101 lactose Substances 0.000 claims abstract 2
- 239000006041 probiotic Substances 0.000 claims abstract 2
- 235000018291 probiotics Nutrition 0.000 claims abstract 2
- 239000003381 stabilizer Substances 0.000 claims abstract 2
- 239000008107 starch Substances 0.000 claims abstract 2
- 235000019698 starch Nutrition 0.000 claims abstract 2
- 230000003612 virological effect Effects 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000654 additive Substances 0.000 claims 4
- 102000007501 Thymosin Human genes 0.000 claims 3
- 108010046075 Thymosin Proteins 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000027244 Dysbiosis Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000002134 immunopathologic effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 abstract 3
- 238000007792 addition Methods 0.000 abstract 3
- 238000004108 freeze drying Methods 0.000 abstract 3
- 206010054094 Tumour necrosis Diseases 0.000 abstract 2
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 abstract 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 241000194031 Enterococcus faecium Species 0.000 abstract 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 244000005706 microflora Species 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
FIELD: biotechnology, medicinal veterinary. SUBSTANCE: preparation has the live bacterium cells obtained by lyophilization that are representatives of normal microflora in health animal intestine, and hybrid protein consisting of tumor necrosis α-factor and thymosine aat the following ratio of components, wt.-%: aluminium oxide 5; starch 4; bacterial mass 0.5; dry immunomodulating agent 0.1, and glucose hydrate - the rest. Dry immunomodulating agent consists of hybrid protein thymosine α- tumor necrosis α-factor - thymosine-aobtained by lyophilization and salt buffer system at the following ratio of components, wt.-%: hybrid protein 0.0008-0.0015; stabilizing additions 1-8; salt buffer system 1.03-1.06, and water - the rest. Stabilizing additions: polyglucin and lactose; salt buffer system: sodium chloride saline solution. Bacterial mass: biomass of Bifidobacterium globosum and Streptococcus faecium obtained by lyophilization at the following ratio of components, wt.-%: dry biomass 70-80, and stabilizing agent 25-30. Stabilizing addition: dry aluminium hydroxide. Preparation is the tabletted form fors oral use exhibiting immunocorrecting action that can be used at viral and bacterial diseases and as probiotic agent. EFFECT: improved method of preparing, enhanced effectiveness.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU95107090/13A RU95107090A (en) | 1995-05-05 | 1995-05-05 | Immunoprobiotic preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU95107090/13A RU95107090A (en) | 1995-05-05 | 1995-05-05 | Immunoprobiotic preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU95107090A true RU95107090A (en) | 1997-03-27 |
Family
ID=48433425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU95107090/13A RU95107090A (en) | 1995-05-05 | 1995-05-05 | Immunoprobiotic preparation |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU95107090A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2169574C1 (en) * | 2000-01-27 | 2001-06-27 | Кобатов Алексей Иванович | Method of biopreparation preparing and dry biopreparation |
-
1995
- 1995-05-05 RU RU95107090/13A patent/RU95107090A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2169574C1 (en) * | 2000-01-27 | 2001-06-27 | Кобатов Алексей Иванович | Method of biopreparation preparing and dry biopreparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0555618B1 (en) | Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria | |
| EP0923293B1 (en) | Treatment of diarrhea | |
| CA2992354C (en) | Self-film-forming composition for oral care | |
| JP4667568B2 (en) | Immune enhancing composition | |
| CA2944118C (en) | Topical composition for use in the treatment of inflammatory bowel disease | |
| BR112012018813B1 (en) | composition comprising bacterial strains with anti-inflammatory, immunomodulating, anti-abdominal or anti-distension properties, use of these strains, as well as pharmaceutical, veterinary and edible products comprising said composition | |
| BRPI0017622B1 (en) | lactic acid bacterial composition and use of the lactic acid bacterial combination for the prevention and / or treatment of infections and inflammatory conditions | |
| CN1211189A (en) | Urogenital and intestinal disorder compositions comprising a substrance derived from plant species of the ericaceae family and a lactic acid bacteria growth factor | |
| AU2025213694A1 (en) | Strains, composition and method of use | |
| CN117187096A (en) | Coli strain for improving intestinal barrier function and application thereof | |
| JPH07108857B2 (en) | Bacterial preparations for the prevention and treatment of inflammatory processes and allergic diseases | |
| JPH07126177A (en) | Ulcerative colitis remedy | |
| US6726913B1 (en) | Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes | |
| US8278089B2 (en) | Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine | |
| RU95107090A (en) | Immunoprobiotic preparation | |
| CA2383626A1 (en) | Treatment of dermal tumors, warts, and viral infections using heat-killed p. acnes | |
| Wertlake et al. | Septicaemia caused by Neisseria flavescens | |
| JP7623379B2 (en) | ASSOCIATION OF FAECALIBACTERIUM PRAUSNITZII STRAIN CNCM I-4573 WITH PENTASA® FOR THE TREATMENT AND PREVENTION OF GASTROENTERITIS | |
| JPH04335885A (en) | Anti-herpes virus-anti-disease drug and food additive | |
| JPWO2014119605A1 (en) | Stable composition containing bifidobacteria | |
| RU2101020C1 (en) | Preparation showing immunostimulating effect | |
| RU2415684C2 (en) | Pharmaceutical composition for treatment and/or prevention of intestinal disbiosis in process of antibacterial therapy in warm-blooded animals: cattle, pigs, domestic animals, in particular dogs, cats and poultry and method of treatment and/or prevention of intestinal disbiosis in process of antibacterial therapy in warm-blooded animals: cattle, pigs, domestic animals, in particular dogs, cats and poultry | |
| WO1995004539A1 (en) | Immunopotentiator and method of immunopotentiating animal with the same | |
| JP4461727B2 (en) | External preparation composition | |
| JPS61260023A (en) | Bifidobacteria and other useful lactic acid bacteria growth agents |